Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Cancer Research

• Publication date

  2013-02-05

• Fields of study

  Biology, Medicine, Engineering

• Identifiers
  DOI 10.1158/1078-0432.CCR-12-2764PMID 23386691PMCID PMC3618564
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy.

  2013cited by this paper
• Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution.

  2012influential reference
• Cooperative, Nanoparticle‐Enabled Thermal Therapy of Breast Cancer

  2012cited by this paper
• Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice

  2012influential reference
• Nanovector delivery of siRNA for cancer therapy

  2012cited by this paper
• Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics.

  2011cited by this paper
• Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer

  2011cited by this paper
• Size and shape effects in the biodistribution of intravascularly injected particles.

  2010cited by this paper
• Frontiers in cancer nanomedicine: directing mass transport through biological barriers.

  2010cited by this paper
• Sustained small interfering RNA delivery by mesoporous silicon particles.

  2010influential reference
• Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer

  2010cited by this paper
• Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles.

  2010cited by this paper
• Experimental therapies: Vectoring siRNA therapeutics into the clinic

  2010cited by this paper
• Beyond chemotherapy: targeted therapies in ovarian cancer

  2009cited by this paper
• EphA2 overexpression is associated with angiogenesis in ovarian cancer

  2007influential reference
• Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.

  2006cited by this paper
• Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

  2005influential reference
• Focal Adhesion Kinase Silencing Augments Docetaxel-Mediated Apoptosis in Ovarian Cancer Cells

  2005cited by this paper
• Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

  2004cited by this paper
• EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma

  2004cited by this paper
• Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival.

  2003cited by this paper
• Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

  2003cited by this paper
• EphA2 overexpression causes tumorigenesis of mammary epithelial cells.

  2001cited by this paper
• The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.

  2001cited by this paper
• Overexpression of the EphA2 tyrosine kinase in prostate cancer

  1999cited by this paper
• Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells.

  1997cited by this paper
• Cáncer

  1939cited by this paper

• Strategies, Challenges, and Prospects of Nanoparticles in Gynecological Malignancies

  2024cites this paper
• Co-Delivery of siRNA and Docetaxel to Cancer Cells by NLC for Therapy

  2024cites this paper
• Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer

  2024cites this paper
• Liposomal nanocarriers containing siRNA as small molecule-based drugs to overcome cancer drug resistance.

  2023cites this paper
• Eph receptors and ephrins in cancer progression

  2023cites this paper
• Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches.

  2022cites this paper
• A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine

  2022cites this paper
• Effects of nanoparticle-mediated Co-delivery of bFGF and VEGFA genes to deep burn wounds: An in vivo study.

  2021cites this paper
• Emerging Gene Knockdown Technology Using Small Interfering RNA in Ovarian Cancer

  2021cites this paper
• Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine

  2021cites this paper
• Nanotechnology advances in ovarian cancer

  2021cites this paper
• Advances in cancer theranostics using organic-inorganic hybrid nanotechnology

  2021cites this paper
• PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway

  2021cites this paper
• A modified porous silicon microparticle promotes mucosal delivery of SARS-CoV-2 antigen and induction of potent and durable systemic and mucosal T helper 1 skewed protective immunity

  2021cites this paper
• siRNA and Ovarian Cancer

  2021cites this paper
• Eph/ephrin family proteins and therapeutic resistance

  2020cites this paper
• Adaptive RSK‐EphA2‐GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer

  2020cites this paper
• Cancer biology functional genomics: From small RNAs to big dreams

  2020cites this paper
• Nanoparticle delivery systems to combat drug resistance in ovarian cancer.

  2020cites this paper
• Liposome-Embedding Silicon Microparticle for Oxaliplatin Delivery in Tumor Chemotherapy

  2020cites this paper
• National Cancer Institute Alliance for nanotechnology in cancer-Catalyzing research and translation toward novel cancer diagnostics and therapeutics.

  2019cites this paper
• Peptide-mediated delivery of therapeutic mRNA in ovarian cancer.

  2019cites this paper
• Investigation of parameters that determine Nano-DC vaccine transport

  2019cites this paper
• NCI Alliance for Nanotechnology in Cancer – Catalysing Research and Translation Towards Novel Cancer Diagnostics and Therapeutics

  2019cites this paper
• Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates

  2019cites this paper
• PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis

  2019cites this paper
• Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes

  2019cites this paper
• Special Section on Drug Delivery Technologies — Minireview Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes

  2019cites this paper
• Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery

  2019cites this paper
• Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity

  2019cites this paper
• Systematic comparison of methods for determining the in vivo biodistribution of porous nanostructured injectable inorganic particles.

  2019cites this paper
• Engineering functional inorganic-organic hybrid systems: advances in siRNA therapeutics.

  2018cites this paper
• Trends towards Biomimicry in Theranostics

  2018cites this paper
• siRNA in ovarian cancer - Delivery strategies and targets for therapy.

  2018influential citation
• Understanding the Connection between Nanoparticle Uptake and Cancer Treatment Efficacy using Mathematical Modeling

  2018cites this paper
• Targeting Alzheimer's disease with gene and cell therapies

  2018cites this paper
• Tailoring Porous Silicon for Biomedical Applications: From Drug Delivery to Cancer Immunotherapy

  2018cites this paper
• Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer

  2018cites this paper
• Advances in Porous Silicon–Based Nanomaterials for Diagnostic and Therapeutic Applications

  2018cites this paper
• Post-nano strategies for drug delivery: Multistage porous silicon microvectors.

  2017cites this paper
• Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.

  2017cites this paper
• Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.

  2017cites this paper
• Chemotherapy with Porous Silicon

  2016cites this paper
• Theory and Experimental Validation of a Spatio-temporal Model of Chemotherapy Transport to Enhance Tumor Cell Kill

  2016cites this paper
• Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

  2016cites this paper
• RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?

  2016cites this paper
• Multi-Approach Design and Fabrication of Hybrid Composites for Drug Delivery and Cancer Therapy

  2016cites this paper
• Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside

  2016cites this paper
• Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey.

  2016cites this paper
• Measuring the Surface-Surface Interactions Induced by Serum Proteins in a Physiological Environment.

  2016cites this paper
• Targeted Delivery of Shear Stress-Inducible Micrornas by Nanoparticles to Prevent Vulnerable Atherosclerotic Lesions.

  2016cites this paper
• A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.

  2016cites this paper
• In Situ Reductive Synthesis of Structural Supported Gold Nanorods in Porous Silicon Particles for Multifunctional Nanovectors.

  2016cites this paper
• Nanomedicine Activities in the United States and Worldwide

  2016cites this paper
• AB137. Decreased expression of receptor tyrosine kinase of EphB1 protein in renal cell carcinomas

  2016cites this paper
• The potential of porous silicon particles for multi-epitopic vaccine development

  2016cites this paper
• Silicon Nanoparticles and Microparticles

  2016cites this paper
• E-selectin-targeting delivery of microRNAs by microparticles ameliorates endothelial inflammation and atherosclerosis

  2016cites this paper
• Redirecting Transport of Nanoparticle Albumin-Bound Paclitaxel to Macrophages Enhances Therapeutic Efficacy against Liver Metastases.

  2016cites this paper
• Nanotherapeutics: From Laboratory to Clinic

  2016cites this paper
• A novel biosensor for quantitative monitoring of on-target activity of paclitaxel.

  2015cites this paper
• Chemical surface modification of porous silicon nanoparticles for cancer therapy

  2015cites this paper
• Eph receptors and ephrins: therapeutic opportunities.

  2015cites this paper
• Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response.

  2015cites this paper
• Recent advances in siRNA delivery

  2015cites this paper
• PLGA-Mesoporous Silicon Microspheres for the in Vivo Controlled Temporospatial Delivery of Proteins.

  2015cites this paper
• Porous silicon microparticles for delivery of siRNA therapeutics.

  2015cites this paper
• Effective modulation of transforming growth factor-β1 expression through engineered microRNA-based plasmid-loaded nanospheres.

  2015cites this paper
• Cholesterol‐loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice

  2015cites this paper
• New Developments in Liposomal Drug Delivery.

  2015cites this paper
• Preclinical and clinical development of siRNA-based therapeutics.

  2015cites this paper
• The potentials of nanotechnology-based drug delivery system for treatment of ovarian cancer

  2015cites this paper
• Circulating Peptidome to Indicate the Tumor-resident Proteolysis

  2015cites this paper
• Multistage vector delivery of sulindac and silymarin for prevention of colon cancer.

  2015cites this paper
• Multistage vector (MSV) therapeutics.

  2015cites this paper
• High-content Analysis of Antibody Phage-display Library Selection Outputs Identifies Tumor Selective Macropinocytosis-dependent Rapidly Internalizing Antibodies*

  2014cites this paper
• Silicon-Based Nanoagents for Cancer Therapy

  2014cites this paper
• Drug Delivery with Porous Silicon

  2014cites this paper
• Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer.

  2014cites this paper
• Opportunities for nanotheranosis in lung cancer and pulmonary metastasis

  2014cites this paper
• Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells.

  2014cites this paper
• Bone marrow endothelium-targeted therapeutics for metastatic breast cancer.

  2014cites this paper
• Anticancer use of nanoparticles as nucleic acid carriers.

  2014cites this paper
• In vivo evaluation of porous silicon and porous silicon solid lipid nanocomposites for passive targeting and imaging.

  2014cites this paper
• Emerging nanotherapeutic strategies in breast cancer.

  2014cites this paper
• Transient Mild Hyperthermia Induces E-selectin Mediated Localization of Mesoporous Silicon Vectors in Solid Tumors

  2014cites this paper
• Ephrin type-A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3-kinase/Akt signalling pathway

  2014cites this paper
• Multivalent Presentation of MPL by Porous Silicon Microparticles Favors T Helper 1 Polarization Enhancing the Anti-Tumor Efficacy of Doxorubicin Nanoliposomes

  2014cites this paper
• Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics.

  2014cites this paper
• Biocompatibility of porous silicon for biomedical applications

  2014cites this paper
• The effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulation.

  2014cites this paper
• Decreased expression of receptor tyrosine kinase of EphB1 protein in renal cell carcinomas.

  2014cites this paper
• DUAL ASSEMBLY NANOPARTICLES ACHIEVE SUSTAINED SILENCING OF ZNF304: A NOVEL TRANSCRIPTION FACTOR FOR Β1 INTEGRIN

  2014cites this paper
• Porous Silicon-Based Multicomposites for Controlled Drug Delivery

  2014cites this paper
• Original Article Decreased expression of receptor tyrosine kinase of EphB1 protein in renal cell carcinomas

  2014cites this paper
• Convergence of Nanotechnology and Cancer Prevention: Are We There Yet?

  2014cites this paper
• Delivery of gene silencing agents for breast cancer therapy

  2013cites this paper
• High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics.

  2013cites this paper
• Problems in (nano)medical mechanics

  2013cites this paper
• Porous silicon advances in drug delivery and immunotherapy.

  2013cites this paper